These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30425563)

  • 1. Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone.
    Webster LR; Israel RJ
    J Pain Res; 2018; 11():2509-2516. PubMed ID: 30425563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
    Rauck R; Slatkin NE; Stambler N; Harper JR; Israel RJ
    Pain Pract; 2017 Jul; 17(6):820-828. PubMed ID: 27860208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study.
    Michna E; Blonsky ER; Schulman S; Tzanis E; Manley A; Zhang H; Iyer S; Randazzo B
    J Pain; 2011 May; 12(5):554-62. PubMed ID: 21429809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis.
    Viscusi ER; Barrett AC; Paterson C; Forbes WP
    Reg Anesth Pain Med; 2016; 41(1):93-8. PubMed ID: 26650429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies.
    Chamberlain BH; Rhiner M; Slatkin NE; Stambler N; Israel RJ
    J Pain Res; 2021; 14():2687-2697. PubMed ID: 34512008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials.
    Mehta N; Slatkin NE; Israel RJ; Stambler N
    F1000Res; 2021; 10():891. PubMed ID: 34631030
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis.
    Michna E; Weil AJ; Duerden M; Schulman S; Wang W; Tzanis E; Zhang H; Yu D; Manley A; Randazzo B
    Pain Med; 2011 Aug; 12(8):1223-30. PubMed ID: 21810165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Tolerability of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A Responder Analysis of 2 Randomized, Placebo-Controlled Trials.
    Nalamachu SR; Pergolizzi J; Taylor R; Slatkin NE; Barrett AC; Yu J; Bortey E; Paterson C; Forbes WP
    Pain Pract; 2015 Jul; 15(6):564-71. PubMed ID: 24815199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain.
    Webster LR; Israel RJ
    J Pain Res; 2018; 11():1503-1510. PubMed ID: 30147355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical Trials.
    Shah ED; Chamberlain BH; Rhiner M; Slatkin NE; Stambler N; Israel RJ
    J Pain Res; 2023; 16():395-406. PubMed ID: 36798078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain.
    Rauck RL; Slatkin NE; Stambler N; Israel RJ
    J Pain Res; 2019; 12():139-150. PubMed ID: 30613162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain.
    Webster LR; Brenner DM; Barrett AC; Paterson C; Bortey E; Forbes WP
    J Pain Res; 2015; 8():771-80. PubMed ID: 26586963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review.
    Mehta N; O'Connell K; Giambrone GP; Baqai A; Diwan S
    Postgrad Med; 2016; 128(3):282-9. PubMed ID: 26839023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial.
    Webster LR; Michna E; Khan A; Israel RJ; Harper JR
    Pain Med; 2017 Aug; 18(8):1496-1504. PubMed ID: 28810695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery.
    Anissian L; Schwartz HW; Vincent K; Vincent HK; Carpenito J; Stambler N; Ramakrishna T
    J Hosp Med; 2012 Feb; 7(2):67-72. PubMed ID: 21998076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness.
    Mehta N; Slatkin NE; Israel RJ; Stambler N; Shah ED
    J Pain Res; 2023; 16():3529-3543. PubMed ID: 37881233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis.
    Peacock WF; Slatkin NE; Israel RJ; Stambler N
    J Emerg Med; 2022 Feb; 62(2):231-239. PubMed ID: 34893381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms.
    Iyer SS; Randazzo BP; Tzanis EL; Schulman SL; Zhang H; Wang W; Manley AL
    Value Health; 2011 Jan; 14(1):177-83. PubMed ID: 21211500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation.
    Liao SS; Slatkin NE; Stambler N
    Drugs Aging; 2021 Jun; 38(6):503-511. PubMed ID: 33788162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose.
    Chamberlain BH; Rhiner M; Slatkin NE; Stambler N; Israel RJ
    J Pain Res; 2023; 16():2595-2607. PubMed ID: 37533563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.